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The thiazolidinediones (TZDs) are synthetic peroxi-
some proliferator-activated receptor  (PPAR) ligands
that promote increased insulin sensitivity in type II di-
abetic patients. In addition to their ability to improve
glucose homeostasis, TZDs also exert anti-proliferative
effects by a mechanism that is unclear. Our laboratory
has shown that two TZDs, ciglitazone and troglitazone,
rapidly induce calcium-dependent p38 mitogen-acti-
vated protein kinase (MAPK) phosphorylation in liver
epithelial cells. Here, we further characterize the mech-
anism responsible for p38 MAPK activation by PPAR
ligands and correlate this with the induction of endo-
plasmic reticulum (ER) stress. Specifically, we show
that TZDs rapidly activate the ER stress-responsive pan-
creatic eukaryotic initiation factor 2 (eIF2) kinase or
PKR (double-stranded RNA-activated protein kinase)-
like endoplasmic reticulum kinase/pancreatic eIF2 ki-
nase, and that activation of these kinases is correlated
with subsequent eIF2 phosphorylation. Interestingly,
PPAR ligands not only activated calcium/calmodulin-
dependent kinase II (CaMKII) 2-fold over control, but
the selective CaMKII inhibitor, KN-93, attenuated
MKK3/6 and p38 as well as PKR and eIF2 phosphoryl-
ation. Although CaMKII was not affected by inhibition
of PKR with 2-aminopurine, phosphorylation of MKK3/6
and p38 as well as eIF2 were significantly reduced.
Collectively, these data provide evidence that CaMKII is
a regulator of PKR-dependent p38 and eIF2 phospho-
rylation in response to ER calcium depletion by TZDs.
Furthermore, using structural derivatives of TZDs that
lack PPAR ligand-binding activity as well as a PPAR
antagonist, we show that activation of these kinase sig-
naling pathways is PPAR-independent.
The thiazolidinedione (TZD)1 drug class was created over 20
years ago with the synthesis of ciglitazone, an analog of the
hypolipidemic agent clofibrate (1). The TZDs have since grown
to include three other members, troglitazone, rosiglitazone,
and pioglitazone, which function to improve metabolic control
in patients with type II diabetes by increasing insulin sensitiv-
ity in adipose tissue, muscle, and liver (2). Following their
discovery, it was learned that TZDs are ligands for the gamma
isoform of the peroxisome proliferator-activated receptor
(PPAR) (3). From this, it was understood that these agents
exert their insulin-sensitizing effects primarily through PPAR-
dependent transcription of genes involved in glucose and lipid
metabolism and energy balance.
In addition to their ability to promote effective glycemic
control, TZDs have also been shown to exert growth inhibitory
effects in multiple cell and animal models (4–7). This is con-
sistent with the observation that PPAR is both necessary and
sufficient to promote adipocyte differentiation (8). However,
the sensitivity of various cell lines to TZD-induced growth
inhibition does not correlate with levels of PPAR expression
(9). This suggests that TZDs have distinct PPAR-independent
effects that are important for these additional, unanticipated
mechanisms of action. In support of this hypothesis, troglita-
zone was shown to equally inhibit proliferation of both
PPAR/ and PPAR/ mouse embryonic stem cells (10). In
addition, structural derivatives of ciglitazone and troglitazone
that lack PPAR ligand-binding activity were demonstrated to
prevent growth of prostate cancer cells.2 Interestingly, these
derivatives exhibited more potent growth inhibitory effects
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than their parent analogs. Collectively, these data support the
growing list of evidence that TZDs have potentially important
PPAR-independent or “non-genomic” effects.
Both our laboratory and others have shown that TZDs influ-
ence mitogen-activated protein kinase (MAPK) activity (11–
14). The three best characterized mammalian MAPKs, extra-
cellular signal-regulated kinase (Erk), p38, and c-Jun
N-terminal kinase (JNK), are known to play important roles in
coordinating a variety of cellular processes, including growth,
differentiation, and, in some cases, apoptosis (15). MAPKs are
activated via a three-tiered, phospho-relay mechanism
whereby a MAPK kinase kinase (MKKK or MEKK) phospho-
rylates an MAPK kinase (MKK or MEK), which subsequently
phosphorylates a MAPK. For example, p38 is selectively phos-
phorylated by MKK3 and MKK6 (16, 17); on the other hand,
multiple MEKKs are known to converge on a particular MKK
(18). This increases the complexity and selectivity of these
signaling pathways such that distinct MAPK cascades can be
activated both independently and simultaneously in a stimu-
lus-specific manner. In general, the Erk pathway is activated
primarily by mitogens, whereas JNK and p38 are preferen-
tially activated by environmental stresses and inflammatory
cytokines. Activation of MAPKs results in phosphorylation of
transcription factors that increase the expression of target
genes. Thus, in addition to their PPAR ligand-binding activ-
ity, the ability of TZDs to induce MAPK phosphorylation may
represent an additional pathway by which these agents affect
cell growth and differentiation. It is therefore important to
understand how these agents induce MAPK signaling as well
as to determine the role of PPAR in this process.
We previously characterized the mechanism by which cigli-
tazone and troglitazone acutely activate members of the MAPK
family in GN4 rat liver epithelial cells (11). Interestingly, our
data suggest that PPAR is not required for TZD-induced
MAPK phosphorylation. In the current study, we have utilized
the aforementioned structural derivatives of ciglitazone and
troglitazone that are devoid of PPAR ligand-binding activity
in addition to a PPAR antagonist to provide definitive evi-
dence that MAPK activation by TZDs in GN4 cells is indeed
PPAR-independent. Additionally, we have further character-
ized the mechanism responsible for p38 activation by TZDs and
provide evidence suggesting a link between p38 activation and
induction of endoplasmic reticulum stress.
EXPERIMENTAL PROCEDURES
Materials—The thiazolidinediones ciglitazone and troglitazone, PP2,
PP3, and KN-93 were purchased from Biomol. 2-Ciglitazone and 2-
troglitazone, TZD derivatives with attenuated PPAR ligand-binding
activity, were synthesized as described.2 These compounds were pre-
pared as stock solutions in Me2SO and were added to cells in media with
a final Me2SO concentration of 0.1%. TPA, 2-aminopurine, and thapsi-
gargin were purchased from Sigma, whereas KN-92 was obtained from
Calbiochem. GW9662 was from Cayman Chemical. Anti-phospho Erk
monoclonal antibody (E-4), anti-Erk polyclonal antibody (C-14), anti-
p38 polyclonal antibody (C-20-G), anti-PKR polyclonal antibody (M-
515), anti-phosphotyrosine (pan) (PY99) monoclonal antibody, and anti-
actin polyclonal antibody (I-19) were all from Santa Cruz
Biotechnology. Anti-phospho EGFR (Tyr845), anti-EGFR, anti-phospho
MKK3/6 (Ser189/Ser207), anti-phospho p38 (Thr180/Thr182), anti-phospho
PERK (Thr980), anti-phospho PKR (Thr446), and anti-phospho eIF2
(Ser51) polyclonal antibodies were purchased from Cell Signaling. Anti-
Pyk2 monoclonal antibody was from BD Transduction Laboratories.
Anti-EGFR C-terminal polyclonal antibody (#22) and anti-Pyk2 C-ter-
minal polyclonal antibody (#72) were generated as previously described
(19, 20). [-32P]ATP was purchased from PerkinElmer Life Sciences.
The recombinant adenoviral vector encoding the C terminus of Pyk2,
termed CRNK (21), (Ad.CRNK) was constructed and amplified as pre-
viously described (22).
Cell Culture—GN4 rat liver epithelial cells were grown in Richter’s
minimal essential medium supplemented with 10% heat-inactivated
FBS and penicillin/streptomycin as detailed earlier (23). A549 human
lung carcinoma cells were purchased from ATCC and similarly propa-
gated in Dulbecco’s modified Eagle’s medium/Nutrient mixture F-12
(1/1) supplemented with serum and antibiotics as above as well as 1.5
g/L sodium bicarbonate and 2 mM L-glutamine. Prior to experiments,
cells at 70–80% confluency were serum-starved overnight in the appro-
priate medium containing 0.1% FBS.
Cell Lysate Preparation—Following stimulation for the times indi-
cated, media was aspirated and the cells were rinsed twice with ice-cold
phosphate-buffered saline. The cells were then scraped into ice-cold
radioimmune precipitation assay buffer (150 mM NaCl, 9.1 mM
Na2HPO4, 1.7 mM NaH2PO4, 1% Nonidet P-40, 0.5% sodium deoxy-
cholate, and 0.1% SDS, pH 7.4) with freshly added 200 M Na3VO4, 250
M phenylmethylsulfonyl fluoride, 5 g/ml leupeptin, and 10 nM micro-
cystin. To analyze changes in PERK, PKR, and eIF2 phosphorylation,
cells were lysed in ice-cold HEPES buffer (20 mM HEPES, pH 7.3, 50
mM NaF, 10% glycerol, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA)
supplemented with 1 mM Na3VO4, 500 M phenylmethylsulfonyl fluo-
ride, and 1 g/ml leupeptin. The cell lysates were clarified by centrifu-
gation at 14,000 rpm for 10 min at 4 °C. Protein concentration was
determined using the Coomassie protein assay reagent (Pierce).
Immunoblotting—In a typical experiment, 10 g of cell lysate was
resuspended in SDS-PAGE sample buffer (0.5 M Tris, pH 6.8, 4% SDS,
20% glycerol, 10% -mercaptoethanol, 0.1% bromphenol blue) and
heated at 95 °C for 5 min to denature proteins. Lysates were then
resolved by SDS-PAGE on Novex pre-cast 10% Tris-glycine gels (In-
vitrogen) and transferred to polyvinylidene fluoride (Immobilon-P, Mil-
lipore). Immunoblots were incubated with the appropriate primary
antibody overnight at 4 °C, washed 3 with TBST, and probed with
horseradish peroxidase-conjugated secondary antibodies for 1 h at room
temperature. Immunoblots were then developed with ECL (Amersham
Pharmacia Biotech) according to the manufacturer’s instructions and
visualized by autoradiography (X-Omat Blue film, Eastman Kodak). In
certain instances, membranes were stripped in buffer (62.5 mM Tris, pH
6.7, 2% SDS, 100 mM -mercaptoethanol) at 55 °C for 30 min and
reprobed with another antibody.
Immunoprecipitation—Following stimulation, cells were rinsed as
described above and scraped into ice-cold radioimmune precipitation
assay buffer without SDS. The lysates were cleared by centrifugation.
300 g of cell lysate was immunoprecipitated by incubation with the
appropriate primary antibody overnight at 4 °C under slight agitation.
Fifteen microliters of Protein A-agarose beads (Santa Cruz Biotechnol-
ogy) were added to each sample, which were then incubated an addi-
tional hour at 4 °C. Immune complexes were collected by brief centrif-
ugation and washed four times in ice-cold lysis buffer. Remaining wash
buffer was carefully removed with a Hamilton syringe. Immune com-
plexes were then resuspended in SDS-PAGE sample buffer and re-
solved by SDS-PAGE as described above.
In Vitro CaMKII Kinase Assay—CaMKII kinase activity in stimu-
lated GN4 cells was measured using a commercial CaMKII assay kit
(Upstate Biotechnology) according to the manufacturer’s instructions
with slight modification. Briefly, CaMKII was immunoprecipitated
from 400 g of cell lysate in HEPES binding buffer (20 mM HEPES, pH
7.7, 50 mM NaCl, 2.5 mM MgCl2, 0.1 mM EDTA, 0.5% Triton X-100) by
overnight incubation with an anti-CaMKII antibody (H-300, Santa
Cruz Biotechnology). CaMKII activity present in immune complexes
was assessed by measuring the transfer of the -phosphate of
[-32P]ATP to a specific CaMKII substrate peptide for 10 min at 30 °C.
Phosphorylated substrate was then separated from residual [-32P]ATP
using P-81 phosphocellulose paper (Whatman) and quantified with a
scintillation counter.
RESULTS
Src-dependent Activation of EGFR and Erk by Ciglitazone
Does Not Require PPAR—Previously, we have shown that
ciglitazone-induced Erk phosphorylation in rat liver epithelial
(GN4) cells required Src-dependent EGFR transactivation (11).
Interestingly, Src kinase activity was unaffected by a PPAR
antagonist suggesting that ciglitazone activates this signaling
pathway via a non-genomic mechanism. We recently obtained
derivatives of two thiazolidinediones, 2-ciglitazone and 2-
troglitazone (Fig. 1), which completely lack PPAR ligand-
binding activity.2 Because pharmacological inhibitors often
have nonspecific effects, we tested whether 2-ciglitazone re-
tained the ability to activate EGFR and Erk in GN4 cells.
Similar to ciglitazone, treatment of GN4 cells with 2-ciglita-
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zone induced rapid, robust EGFR phosphorylation that corre-
lated with Erk activation (Fig. 2, A and B). In contrast, 2-
troglitazone failed to significantly activate EGFR and Erk,
consistent with our previous finding that troglitazone was a
much weaker Erk activator than ciglitazone in GN4 cells (11).
These data demonstrate that the 2-derivatives act similarly to
their parent compounds with respect to EGFR and Erk
phosphorylation.
Because Src is required for EGFR transactivation and down-
stream Erk phosphorylation by ciglitazone (11), we tested
whether this kinase played a similar, necessary role in signal-
ing events following exposure to 2-ciglitazone. Using an anti-
body that recognizes the EGFR when phosphorylated at Tyr845,
a putative Src-specific phosphorylation site (24), we observed
that 2-ciglitazone, like ciglitazone, induced Tyr845 phospho-
rylation (Fig. 3). Pretreatment of cells with PP2, a selective Src
kinase inhibitor, completely blocked 2-ciglitazone-induced
EGFR phosphorylation at Tyr845 as well as downstream Erk
activation. In contrast, pretreatment of cells with PP3, a phar-
macologically inactive analog of PP2, did not affect the ability
of 2-ciglitazone to induce either EGFR or Erk phosphoryla-
tion. Thus, these data show that EGFR transactivation as well
as Erk phosphorylation by 2-ciglitazone requires Src. Collec-
tively, these findings corroborate our earlier studies using a
PPAR antagonist and, importantly, provide additional evi-
dence that TZDs activate PPAR-independent kinase signaling
pathways in GN4 cells.
2-Thiazolidinediones Are Less Effective Activators of the
p38 MAPK Pathway—In addition to their effects on the EGFR
and Erk, we previously showed that both ciglitazone and tro-
glitazone rapidly activate p38 in GN4 cells (11). PPAR ligand-
induced p38 phosphorylation occurred in an EGFR-independ-
ent manner and was instead correlated with increases in
intracellular calcium and activation of the calcium-dependent
tyrosine kinase Pyk2. Here, we tested whether 2-ciglitazone
and 2-troglitazone retained the ability to similarly activate
Pyk2 and p38. Interestingly, both of the 2-derivatives showed
significantly reduced efficacy in activating p38 when compared
with the parent compounds (Fig. 4A). Examination of MKK3/6,
the MAP kinase kinase immediately upstream of p38, and
Pyk2 phosphorylation (Fig. 4B) revealed similar findings; 2-
ciglitazone and 2-troglitazone failed to activate these kinases
as strongly as ciglitazone and troglitazone, respectively.
To further evaluate the role of PPAR in TZD-dependent p38
activation, we pretreated GN4 cells with the PPAR antagonist
GW9662 prior to stimulation with ciglitazone, troglitazone, or
their respective 2-derivatives. GW9662 failed to inhibit the
ability of ciglitazone or troglitazone to activate MKK3/6 and
p38 (Fig. 4C). Importantly, co-treatment of GN4 cells with
GW9662 and either of the 2-TZDs did not potentiate the lack
of effect on MKK3/6 and p38 phosphorylation in response to
these derivatives alone. Together, these findings suggest that
TZD-induced p38 phosphorylation, like Erk activation, is also
PPAR-independent. In support of this hypothesis, structur-
FIG. 1. Chemical structures of ciglitazone and troglitazone
and their respective 2-derivatives.
FIG. 2. 2-Ciglitazone potently activates the EGFR and Erk,
whereas 2-troglitazone does not. Rat liver epithelial cells (GN4)
were grown to near confluency and starved overnight in media contain-
ing 0.1% FBS. Cells were stimulated with ciglitazone, 2-ciglitazone,
troglitazone, 2-troglitazone (50 M), or Me2SO (DMSO, 0.1%) for 10
min. A, EGFR was immunoprecipitated (IP) from cell lysates, and
samples from immune complexes were resolved by SDS-PAGE. The
immunoblots (IB) were probed with a pan anti-phosphotyrosine anti-
body, PY99, or an anti-EGFR antibody. Blots were developed with ECL
according to the manufacturer’s instructions and visualized by autora-
diography. B, changes in Erk phosphorylation were assessed by immu-
noblot following resolution of cell lysates by SDS-PAGE using an anti-
phospho Erk (p-Erk) antibody. The blots were stripped and reprobed
using antibodies directed against total Erk.
FIG. 3. 2-Ciglitazone-dependent EGFR and Erk phosphoryla-
tion is sensitive to PP2. GN4 cells were preincubated with or without
PP2 or PP3 (10 M, 1 h) followed by stimulation with ciglitazone (Cig,
50 M), 2-ciglitazone (2-Cig, 50 M), or Me2SO (DMSO, 0.1%) for 10
min. Changes in EGFR phosphorylation at Tyr845 as well as changes in
Erk activation were assessed by immunoblotting (IB) with an anti-
phospho EGFR antibody (Y845) and an anti-phospho Erk (p-Erk) anti-
body. Total EGFR and Erk are shown in the lower panels.
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ally related TZDs and more potent PPAR agonists, rosiglita-
zone and pioglitazone, were unable to activate p38 MAPK in
GN4 cells (data not shown).
Role of Pyk2 as an Upstream Activator of p38—Because our
previous studies suggested a link between Pyk2 and p38
MAPK, we further examined if activation of Pyk2 was neces-
sary for the effects of PPAR ligands on p38 phosphorylation.
Specifically, GN4 cells were infected with a recombinant ade-
novirus encoding either bacterial -galactosidase (Ad.lacZ) or a
C-terminal inhibitory form of Pyk2 (Ad.CRNK) prior to stimu-
lation with PPAR ligands. CRNK represents an alternative
potential splice variant of Pyk2 (21), which functions to nega-
tively regulate endogenous Pyk2 autophosphorylation (25). An-
giotensin II-dependent Pyk2 phosphorylation in GN4 cells was
reduced to near basal levels following infection with increasing
amounts of Ad.CRNK with maximal inhibition observed using
4  106 plaque-forming units/ml, a titer that also produced
significant CRNK expression (data not shown). Therefore, this
dose was used in subsequent studies. Although Ad.lacZ had no
affect on PPAR ligand-dependent Pyk2 phosphorylation, over-
expression of CRNK significantly blunted Pyk2 activation by
both ciglitazone and troglitazone (Fig. 5A). Immunoblots from
the same lysates revealed that, in contrast to Pyk2, CRNK
failed to prevent activation of either MKK3/6 or p38 MAPK
(Fig. 5B). These results suggest that independent but parallel,
calcium-regulated signaling pathways activate Pyk2 and p38
in this cell type.
CaMKII but Not PKC Is Required for MKK3/6 and p38 Acti-
vation by PPAR Ligands—Our earlier work with BAPTA-AM
showed that intracellular calcium was required for both Pyk2
and p38 activation in response to PPAR ligands (11). Yet,
PPAR agonist-induced MKK3/6 and p38 phosphorylations are
unaffected by adenoviral-mediated overexpression of a Pyk2
dominant negative, conditions that prevented Pyk2 activation
in response to these drugs. Together, these findings suggest
that an additional calcium-activated kinase is induced by
PPAR ligands, ultimately leading to p38 phosphorylation.
Similar to Pyk2, calcium/calmodulin-dependent kinase II
(CaMKII) and the classic protein kinase Cs (PKC, -, and -)
represent other calcium-regulated kinases that could be acti-
FIG. 4. 2-TZDs are weaker activators of p38 MAPK and Pyk2
in GN4 cells. Serum-starved GN4 cells were stimulated with ciglita-
zone, troglitazone, or their respective 2-derivatives (50 M) for 10 min.
Me2SO (DMSO, 0.1%) served as the vehicle control. A, 10 g of cell
lysate was resolved by SDS-PAGE. Activation of MKK3/6 and p38 were
determined by immunoblotting (IB) with anti-phospho MKK3/6 (p-
MKK3/6) and anti-phospho p38 (p-p38) antibodies, respectively. Blots
were stripped and reprobed for total p38 as described. B, Pyk2 was
immunoprecipitated (IP) from 300 g of cell lysate, and immune com-
plexes were resolved by SDS-PAGE. Immunoblots were probed with a
pan anti-phosphotyrosine, PY99, antibody to detect changes in Pyk2
phosphorylation. Total Pyk2 was assessed using an anti-Pyk2 antibody.
C, prior to stimulation, some cells were preincubated with the PPAR
antagonist, GW9662 (1 M, 1 h).
FIG. 5. Ad.CRNK blunts Pyk2 activation by PPAR ligands
but has no affect on MKK3/6 or p38 phosphorylation. Following
infection of confluent GN4 cells with 4  106 plaque-forming units/ml
Ad.lacZ or Ad.CRNK, cells were serum-starved overnight in media
supplemented with 0.1% FBS prior to stimulation with ciglitazone
(Cig, 50 M), troglitazone (Tro, 50 M), or Me2SO (DMSO, 0.1%) for 10
min. Cell lysates were prepared as detailed under “Experimental
Procedures.” A, Pyk2 was immunoprecipitated (IP) from lysates, and
immune complexes were subjected to SDS-PAGE. The effect of Ad-
.CRNK on Pyk2 phosphorylation was determined by immunoblotting
(IB) with a pan anti-phosphotyrosine, PY99, antibody; total Pyk2 was
assessed using an anti-Pyk2 antibody. B, lysates were resolved di-
rectly by SDS-PAGE, and immunoblotting was performed as de-
scribed in the legend to Fig. 4 to detect changes in MKK3/6 and p38
phosphorylation. To verify equal protein loading, the blots were
stripped and reprobed with an anti-p38 antibody.
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vated by PPAR ligands. To test the involvement of PKC in p38
activation by PPAR agonists, classic PKCs were depleted by
chronic exposure of GN4 cells to TPA. Although PKC depletion
completely prevented transient, TPA-dependent Erk activation
(data not shown), ciglitazone and troglitazone-induced p38
phosphorylation was not affected (Fig. 6A). This result suggests
that classic PKCs are not involved in PPAR ligand-dependent
p38 activation.
To determine whether CaMKII is necessary for p38 phospho-
rylation in response to PPAR agonists, the ability of ciglita-
zone and troglitazone to activate p38 in the presence of the
selective CaMKII inhibitor, KN-93 (26), was evaluated. Inter-
estingly, pretreatment of GN4 cells with KN-93 blocked both
MKK3/6 as well as p38 activation by PPAR ligands (Fig. 6B).
These effects were specific for KN-93, because KN-92, a phar-
macologically inactive analog of KN-93, did not prevent activa-
tion of these kinases.
Further, the ability of ciglitazone and troglitazone to directly
stimulate CaMKII activity was examined. CaMKII was immu-
noprecipitated from cell lysates, and in vitro kinase assays
were performed using a specific substrate peptide. Ciglitazone
and troglitazone significantly increased CaMKII activity 2-fold
over vehicle control within 10 min, a time that coincides with
maximal p38 phosphorylation (Table I). Consistent with its
documented ability to directly inhibit CaMKII (26), KN-93
significantly blunted PPAR ligand-induced CaMKII activa-
tion. In contrast to its effects on CaMKII, MKK3/6, and p38,
KN-93 failed to prevent TZD-induced Pyk2 phosphorylation
(Fig. 6C). Collectively, these findings support our hypothesis
that CaMKII, and not Pyk2, acts upstream of MKK3/6 and p38
in this signaling pathway.
2-Ciglitazone and 2-troglitazone were less effective
MKK3/6 and p38 activators than their parent TZDs in GN4
cells (Fig. 4). Because MKK3/6 and p38 phosphorylation in
response to ciglitazone and troglitazone was KN-93-sensitive,
we assessed whether the 2-derivatives failed to potently acti-
vate CaMKII. Indeed, CaMKII kinase assays revealed that
2-ciglitazone and 2-troglitazone were significantly weaker
CaMKII activators than their parent compounds (Table I).
These data further support our finding that CaMKII is neces-
sary for p38 activation in response to PPAR ligands and is
consistent with the inability of 2-TZDs to effectively induce
MKK3/6 and p38 phosphorylation.
PPAR Ligands Induce ER Stress and eIF2 Phosphoryla-
tion in GN4 Cells—Ciglitazone and troglitazone were reported
to rapidly increase cytosolic calcium by inhibiting capacitative
calcium entry into the endoplasmic reticulum (ER) (10). Cal-
cium is actively involved in proper protein folding and trans-
port within the ER such that its depletion leads to the accu-
mulation of misfolded proteins and subsequent ER stress (27,
28). To test whether PPAR ligands induce ER stress in GN4
cells, we assessed the ability of these compounds to rapidly
phosphorylate PERK, a recently discovered ER-resident serine/
threonine kinase whose activity is increased selectively in re-
sponse to chemical-induced ER stress (29, 30). Immunoblotting
with a phospho-PERK antibody revealed that treatment of
GN4 cells with ciglitazone and troglitazone induced a time-de-
pendent increase in PERK activation (Fig. 7A). We also ob-
FIG. 6. Role of CaMKII and PKC in PPAR ligand-dependent
p38 activation. A, GN4 cells were treated with TPA (1 M, overnight)
followed by acute stimulation with ciglitazone (Cig, 50 M), troglitazone
(Tro, 50 M), or Me2SO (DMSO, 0.1%) for 10 min. Cell lysates were
subjected to anti-phospho p38 (p-p38) immunoblotting (IB) as described
under “Experimental Procedures.” B and C, cells were preincubated
with the selective CaMKII kinase inhibitor, KN-93, or its structurally
inactive analog KN-92 (10 M, 1 h) as indicated, prior to exposure to
PPAR ligands for 10 min. The effect of CaMKII inhibition on PPAR
ligand-induced MKK3/6 and p38 (B) and Pyk2 (C) phosphorylation was
determined by immunoprecipitation and/or immunoblotting as detailed
earlier. Total p38 or Pyk2 is shown in the lower panels.
TABLE I
Activation of CaMKII by PPAR ligands and their 2-derivatives
Serum-starved GN4 cells were treated with ciglitazone (Cig), 2-
ciglitazone (2-Cig), troglitazone (Tro), or 2-troglitazone (2-Tro) (50
M) or Me2SO (0.1%) for 10 min unless otherwise indicated. Some cells
were preincubated with KN-93 (10 M, 1 h) or 2-aminopurine (2-AP; 10
mM, 1 h) prior to stimulation with TZDs. CaMKII activity was evalu-
ated as described under “Experimental Procedures” using an in vitro
kinase assay. Data are reported as mean  S.D. (n  4–7) and repre-
sent the -fold change in activity over the Me2SO control.
CaMKII activity
Treatment -Fold  Me2SO p
Cig 1.5 1.09  0.22a 0.002
Cig 5 1.40  0.05 0.06
Cig 10 1.97  0.44
Cig  KN-93 1.38  0.22b 0.02
2-Cig 1.28  0.24a 0.009
Cig  2-AP 1.64  0.44 0.22
Tro 1.5 1.38  0.42b 0.03
Tro 5 1.50  0.30b 0.04
Tro 10 1.97  0.31
Tro  KN-93 1.46  0.21b 0.013
2-Tro 1.43  0.30b 0.026
Tro  2-AP 1.65  0.34 0.17
a Denotes statistical significant differences from ciglitazone or trogli-
tazone (10-min treatments) as appropriate (p  0.01; one-way ANOVA).
b Denotes statistical significant differences from ciglitazone or trogli-
tazone (10-min treatments) as appropriate (p  0.05; one-way ANOVA).
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served PERK activation in response to thapsigargin, an agent
known to induce ER stress through calcium store depletion
(data not shown). PERK phosphorylation was first observed
	5–10 min following exposure to PPAR ligands and occurred
within the same time frame as activation of other calcium-
regulated signaling pathways (e.g. Pyk2 and CaMKII, MKK3/6,
and p38). Similar to our earlier data, 2-ciglitazone and 2-
troglitazone were unable to activate PERK to the same extent
as the parent compounds (Fig. 7B).
An early response to ER stress is to inhibit protein synthesis
by blocking translation initiation (31). Phosphorylation of the 
subunit of eukaryotic initiation factor 2 (eIF2) at Ser51 by
several protein kinases, including PERK results in an inhibi-
tion of mRNA translation (30, 32–35). Because PPAR ligands
induced PERK activation, we determined whether eIF2 was
also phosphorylated. Using a phospho-specific antibody that
detects eIF2 when phosphorylated at Ser51, we observed that
ciglitazone and troglitazone induced eIF2 phosphorylation at
this site as early as 15 min after treatment and that phospho-
rylation was sustained for at least 1 h (Fig. 8A). Phosphoryla-
tion of eIF2 was also observed in response to thapsigargin
(data not shown). Similar to our observations with PERK,
2-ciglitazone and 2-troglitazone were unable to induce eIF2
phosphorylation to the same extent as ciglitazone and troglita-
zone, respectively (Fig. 8B).
Role of PKR in PPAR Ligand-dependent p38 Activation—
Depletion of ER calcium can also lead to activation of double-
stranded RNA-activated protein kinase or PKR (36). Interest-
ingly, PKR is not only involved in ER stress signaling, but was
also recently shown to contribute to activation of the p38 path-
way in response to both endotoxin and pro-inflammatory cyto-
kines (37). Because PPAR ligand-induced p38 phosphoryla-
tion is accompanied by activation of ER stress signaling
pathways, we tested whether PKR played a role in TZD-de-
pendent MKK3/6 and p38 phosphorylation. Pretreatment of
GN4 cells with 2-aminopurine, an adenine analog inhibitor of
PKR activity (38), reduced MKK3/6 and p38 phosphorylation in
response to PPAR ligands (Fig. 9A). This inhibitory effect was
selective for the p38 pathway, because the EGFR and Erk were
still activated by ciglitazone in the presence of 2-aminopurine
(data not shown). In addition to MKK3/6 and p38, inhibition of
PKR with 2-aminopurine also blunted PPAR agonist-depend-
ent eIF2 phosphorylation (Fig. 9B), a finding consistent with
the established role of PKR as an ER stress-induced eIF2
kinase (39).
Because a PKR inhibitor abolished TZD-dependent activa-
tion of p38 MAPK and ER stress signaling pathways, we as-
sessed whether these compounds affected PKR activity. Be-
cause commercially available phospho-specific PKR antibodies
are marketed for detection of human or mouse PKR, and GN4
cells are not amenable to transfection, we determined the effect
of TZDs on PKR activity in A549 human lung carcinoma cells.
PPAR ligands were recently reported to rapidly induce ER
stress in these cells (40), suggesting that pathways similar to
those we have demonstrated here in GN4 are also activated in
A549. Indeed, stimulation of serum-starved A549 cells with
ciglitazone and troglitazone led to a time-dependent increase in
MKK3/6 and p38 phosphorylation (Fig. 9C). Interestingly, both
TZDs also increased PKR phosphorylation at times that paral-
leled MAPK activation. Similar to our findings in GN4 cells,
troglitazone was a stronger activator of MKK3/6 and p38 than
ciglitazone. Consistent with a role for PKR as an upstream
mediator of TZD-dependent MAPK phosphorylation, troglita-
zone also induced greater PKR activation than ciglitazone.
Furthermore, pretreatment of A549 cells with 2-aminopurine
prior to stimulation with PPAR ligands not only blunted PKR
phosphorylation, as expected, but also decreased TZD-induced
MKK3/6 and p38 activation (Fig. 9D).
CaMKII Is Correlated with PKR Activation in Response to
PPAR Ligands—Collectively, the data presented here sug-
gest a role for both CaMKII and PKR as upstream regulators
of PPAR ligand-dependent p38 activation. To determine if
FIG. 7. PERK is activated by PPAR ligands but not their
2-derivatives. A, serum-starved GN4 cells were exposed to ciglita-
zone (Cig, 50 M), troglitazone (Tro, 50 M), or Me2SO (DMSO, 0.1%) as
a vehicle control for 1.5, 5, or 10 min as indicated. B, cells were treated
with PPAR ligands as described in A or with their 2-derivatives (50
M) for 10 min. Lysates were prepared in HEPES buffer (see “Experi-
mental Procedures”) and resolved by 10% SDS-PAGE. Changes in
PERK phosphorylation were detected by immunoblotting (IB) with an
anti-phospho PERK (p-PERK) antibody. Immunoblotting with an anti-
actin antibody was used to verify equal protein loading.
FIG. 8. Phosphorylation of eIF2 at Ser51 in response to
PPAR ligands and their 2-derivatives. A, GN4 cells were stim-
ulated as described in the legend to Fig. 7 for 15, 30, 45, or 60 min as
indicated. B, cells were treated with PPAR agonists or their respective
2-derivatives (50 M) for 60 min. Increases in eIF2 phosphorylation
at Ser51 were determined by immunoblotting (IB) with an anti-phospho
eIF2 (p-eIF2) antibody. Blots were then stripped and reprobed with
an anti-actin antibody.
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activation of these two kinases are correlated in response to
PPAR agonists, we tested whether PKR inhibition could
influence TZD-induced CaMKII activation. In the presence of
2-aminopurine, PPAR ligand-dependent CaMKII activity
was not affected (Table I), suggesting that CaMKII is acti-
vated independently of PKR. We then performed the converse
of this experiment and assessed whether CaMKII inhibition
influenced PKR activity. Interestingly, the CaMKII inhibitor
KN-93, but not the structurally inactive analog KN-92, sig-
nificantly blunted PPAR ligand-dependent PKR phosphoryl-
ation (Fig. 10A). Similar results were observed for eIF2;
eIF2 phosphorylation in response to ciglitazone and trogli-
tazone was blunted only in the presence of KN-93 (Fig. 10B).
Because activation of p38 in response to ciglitazone and tro-
glitazone was also KN-93- and 2-aminopurine-sensitive, we
determined whether p38 was necessary for eIF2 phospho-
rylation. In contrast to KN-93, inhibition of p38 with
SB203580 had no affect on PPAR ligand-induced eIF2
phosphorylation (data not shown). Because PERK is not only
known to phosphorylate eIF2 in response to ER stress but is
also activated in GN4 cells by ciglitazone and troglitazone,
we tested whether KN-93 affected PPAR ligand-induced
PERK activation. Pretreatment of cells with KN-93 was un-
able to prevent PERK phosphorylation in response to TZDs
(datanotshown).Collectively, thesedatasuggestthatCaMKII-
dependent activation of PKR is critical for both p38 and
eIF2 phosphorylation by PPAR ligands.
DISCUSSION
The observation that PPAR ligands rapidly activate
MAPKs by our laboratory and others (11–14) raises three im-
portant questions: 1) What is the mechanism for activation of
MAPKs by these compounds? 2) Is PPAR ligand-binding ac-
tivity required for MAPK phosphorylation? and 3) Does PPAR
FIG. 9. PKR contributes to PPAR ligand-induced MKK3/6,
p38, and eIF2 phosphorylation. Serum-starved GN4 (A and B) or
A549 (C and D) cells were treated with ciglitazone (Cig, 50 M) or
troglitazone (Tro, 50 M) for 10 min (A), 60 min (B and D), or the
indicated times (C). Prior to stimulation, some cells were preincubated
with 2-aminopurine (2-AP; 10 mM, 1 h). Changes in MKK3/6, p38, PKR,
and eIF2 phosphorylation were assessed by immunoblotting (IB) as
described previously. Equal protein loading was verified by stripping
blots and reprobing with either anti-p38 (A, C, and D) or anti-actin
(B) antibodies.
FIG. 10. CaMKII is correlated with eIF2 phosphorylation by
PPAR ligands. Confluent A549 (A) or GN4 (B) cells were incubated
with either KN-93 or KN-92 (10 M, 1 h) prior to stimulation with
ciglitazone (Cig, 50 M) or troglitazone (Tro, 50 M) for 60 min.
Lysates were prepared as described under “Experimental Proce-
dures.” Anti-phospho PKR and anti-phospho eIF2 antibodies, re-
spectively, were used to determine changes in PKR (A) and eIF2 (B)
phosphorylation. Blots were stripped and reprobed with anti-PKR or
anti-actin antibodies.
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ligand-induced MAPK phosphorylation contribute to the phar-
macological effects of these agents? Our previous work, which
focused on how PPAR agonists activated MAPKs in a rat liver
epithelial cell line, showed that Erk phosphorylation required
Src-dependent EGFR transactivation (11). Moreover, we found
that p38 activation occurred independently of the EGFR and
instead was correlated with Pyk2 phosphorylation and in-
creases in intracellular calcium. In the current study, we have
elaborated on the mechanism of p38 activation by PPAR li-
gands and also determined the role of PPAR in this process.
To directly address the question of whether PPAR is neces-
sary for TZD-induced MAPK activation in GN4 cells, we have
utilized chemical derivatives of these agents that are devoid of
ligand-binding activity. The rationale for synthesizing the 2-
derivatives came from the observation that insertion of a dou-
ble bond adjoining the terminal thiazolidine-2,4-dione ring
abolished PPAR ligand-binding activity (41), presumably due
to increased structural rigidity surrounding the heterocyclic
system. Here, we provide evidence that 2-ciglitazone retained
the ability to induce Src-dependent EGFR phosphorylation and
downstream Erk activation. This clearly shows that PPAR is
not required for TZD-induced Erk phosphorylation in GN4 cells
and supports our earlier studies with a PPAR antagonist (11).
Interestingly, 2-ciglitazone and 2-troglitazone failed to
activate CaMKII, Pyk2, and p38 with the same efficacy as their
parent compounds. Based on our earlier data examining the
effects of ciglitazone and 2-ciglitazone on EGFR/Erk signal-
ing, these findings were both unexpected and intriguing. Al-
though this observation suggests a role for PPAR in these
signaling events, the PPAR antagonist GW9662 had no affect
on TZD-dependent p38 phosphorylation. Moreover, structur-
ally related TZDs with higher PPAR binding affinity do not
activate p38 in this cell model. Together, these observations
suggest that activation of the p38 MAPK pathway in GN4 cells
by ciglitazone and troglitazone is non-genomic. As opposed to a
requirement for PPAR, we propose that the failure of the
2-TZDs to strongly activate p38 results instead from an in-
ability of these compounds to efficiently mobilize calcium from
the ER. This hypothesis is discussed in more detail below.
While investigating the mechanism of PPAR ligand-in-
duced p38 phosphorylation, we observed that p38 and Pyk2 are
activated by parallel but independent pathways (Fig. 11). Al-
though the role of Pyk2 as an upstream activator of p38 MAPK
has been reported in response to several different stimuli (11,
22, 42), the lack of a highly selective Pyk2 inhibitor has made
this difficult to substantiate. CRNK (a C-terminal inhibitory
form of Pyk2) is a Pyk2-targeted inhibitor thought to compete
with the full-length protein for binding partners necessary for
activation (25). Adenovirus expression of CRNK significantly
reduced Pyk2 activation by ciglitazone and troglitazone as ex-
pected, yet had no affect on either MKK3/6 or p38 phosphoryl-
ation by PPAR ligands. Although these data do not refute our
earlier finding that Pyk2 and p38 activations are correlated, it
further defines this mechanism. Specifically, the current stud-
ies illustrate that Pyk2 and p38 phosphorylations in response
to PPAR ligands occur via calcium-dependent pathways that
may be parallel but independent.
The data presented here identify a role for CaMKII in TZD-
induced p38 phosphorylation. CaMKII has previously been im-
plicated as an activator of the p38 MAPK pathway in response
to calcium signals in neurons (43). In the current study, both
ciglitazone and troglitazone time dependently increased
CaMKII kinase activity 	2-fold over vehicle control at times
that coincide with maximal p38 phosphorylation. Moreover, the
selective CaMKII inhibitor KN-93, but not its structurally in-
active analog KN-92, reduced PPAR ligand-dependent
MKK3/6 and p38 activation to near basal levels yet had no
affect on Pyk2 activation. Collectively, these data not only
support our findings with CRNK, but also further suggest that
Pyk2 and p38 are activated by separate pathways. Instead,
CaMKII is a critical upstream activator of p38 phosphorylation
in GN4 cells in response to PPAR ligands. Although PKC is
also activated by increases in intracellular calcium, we found
no evidence (by TPA down-regulation) for involvement of this
kinase family in PPAR agonist-dependent p38 activation.
Similar to our previous findings with BAPTA-AM (11), neither
CRNK overexpression nor KN-93 prevented EGFR and Erk
phosphorylation in response to these compounds (data not
shown). Importantly, this provides further evidence that
PPAR ligands activate two distinct kinase pathways in
GN4 cells.
We hypothesize that the intracellular calcium required for
activation of these kinases in GN4 cells is derived from the
endoplasmic reticulum (ER). Ciglitazone and troglitazone were
previously shown to promote calcium release from the ER lead-
ing to PKR-dependent phosphorylation of eIF2, translation
inhibition, and ultimately growth arrest (10). Together, these
observations suggest that PPAR ligands cause ER stress. In
support of this idea, we show here that TZDs not only induce
eIF2 phosphorylation but also activate PERK and PKR. Al-
though TZD-dependent PKR activation was previously re-
ported (10), this is the first evidence that these compounds also
influence PERK activity; our finding is significant because
PERK phosphorylation was previously observed only in re-
sponse to ER and not cytoplasmic stress (30). Moreover, PERK
and PKR are important for ER stress-induced eIF2 phospho-
FIG. 11. Schematic representation of the proposed mechanism
responsible for MAPK activation by PPAR ligands in GN4 cells.
Stimulation of rat liver epithelial cells with PPAR ligands activates
two distinct, PPAR-independent kinase-mediated signaling cascades
resulting in MAPK phosphorylation. Ciglitazone induces Src-dependent
EGFR transactivation, leading to the recruitment of Grb2 and SOS,
which in turn promote Ras activation and subsequent Erk phosphoryl-
ation. Simultaneously, both ciglitazone and troglitazone induce EGFR-
independent activation of p38 MAPK that is correlated with increases
in intracellular calcium and Pyk2 activation. Specifically, TZDs pro-
mote calcium release from the ER-activating CaMKII and the ER
stress-responsive kinase PERK. CaMKII, most likely via serine phos-
phorylation of PACT, promotes activation of PKR. PKR then facilitates
downstream MKK3/6 and p38 as well as eIF2 phosphorylation. Col-
lectively, modulation of MAPK activity and eIF2 phosphorylation is a
potential mechanism for how TZDs affect cell growth in a PPAR-
independent manner.
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rylation (39, 44). Indeed, a PKR-selective inhibitor attenuated
PPAR ligand-dependent eIF2 phosphorylation in GN4 cells.
Collectively, these data suggest that intracellular calcium mo-
bilization by PPAR ligands in GN4 cells interferes with proper
protein folding in the ER thus promoting ER stress.
These findings have led us to hypothesize that disruptions in
ER calcium homeostasis are not only important for ER stress,
but also provide a mechanistic link identifying the intracellular
source of calcium required for PPAR ligand-induced CaMKII,
Pyk2, and p38 activation (Fig. 11). Evidence for p38 as a trans-
ducer of ER stress has been documented previously, because
this MAPK was shown to phosphorylate multiple ER stress-
induced transcription factors (e.g. activating transcription fac-
tor 2, activating transcription factor 6, and growth arrest and
DNA damage-inducible gene 153), leading to increases in tran-
scriptional activity (45–47). In addition, we provide evidence
here that ER stress-responsive eIF2 kinases are not only
activated by PPAR ligands, but that PKR contributes to
PPAR agonist-dependent MKK3/6 and p38 activation.
Although PKR has been implicated as an upstream activator
of p38 in the innate immune response (37), this is the first
evidence that PKR can influence ER stress-induced p38 phos-
phorylation. Although the mechanism by which PKR activates
p38 remains unclear, it was recently shown that PKR physi-
cally interacts with MKK6 in response to double-stranded
RNA, forming a catalytic complex and thus facilitating p38
phosphorylation (48). These previous studies along with the
current data using 2-aminopurine suggest that PKR acts as an
important upstream mediator of TZD-dependent p38 activa-
tion. However, our findings do not discount the potential role of
additional, unknown MKK kinases that could also contribute to
p38 phosphorylation in this model. Specifically, 2-aminopurine
completely blunts PKR activation in response to PPAR li-
gands, but modest MKK3/6 and p38 phosphorylation is still
observed. Furthermore, the time course for PKR activation in
A549 cells closely parallels rather than precedes that of
MKK3/6 and p38. Although this could be due to a lack of
sensitivity in the immunoblot assay, additional studies in the
current model are necessary to clarify a direct relationship
between PKR and p38 as previously reported in different cell
types. Importantly, these data identify the ER as a potential
key mediator in TZD-induced signaling in GN4 cells (Fig. 11);
however, future studies are needed to determine a causal role
for the ER in this mechanism.
Interestingly, the data presented here support a role for both
CaMKII and PKR as regulators of the p38 MAPK and eIF2
pathways in response to PPAR ligands. Although double-
stranded RNA is the classic PKR stimulus, the activity of this
kinase is also increased in double-stranded RNA-independent
conditions by a novel protein activator PKR-activating protein
(also known as RAX) (49, 50). In response to cellular stresses
such as thapsigargin, PACT is phosphorylated on serine resi-
dues and associates with PKR leading to increases in kinase
activity and eIF2 phosphorylation (50, 51). Although serine
phosphorylation of PACT occurs at putative CaMKII consensus
sites, the kinase responsible for PACT phosphorylation has not
been identified. Based on our current findings, we propose that
CaMKII via PACT activates PKR in response to PPAR li-
gands; PKR then facilitates downstream MKK3/6 and p38 as
well as eIF2 phosphorylation (Fig. 11).
Consistent with their inability to potently activate CaMKII,
Pyk2, and p38, 2-TZDs also failed to induce PERK phospho-
rylation to the same extent as their parent compounds. Thus, in
the pathways we examined in GN4 cells, 2-ciglitazone and
2-troglitazone differ from ciglitazone and troglitazone only in
their ability to activate the “calcium-regulated” kinases. Al-
though we have shown that PPAR ligand-induced Pyk2 and
p38 phosphorylation in GN4 cells is calcium-dependent (11),
activation of PERK, PKR, and CaMKII in response to intracel-
lular calcium release has been documented extensively in the
literature. On the other hand, BAPTA-AM, Ad.CRNK, KN-93,
and 2-aminopurine failed to significantly inhibit PPAR ligand-
dependent EGFR and Erk phosphorylation (data not shown).
This observation suggests that activation of this latter signal-
ing pathway is calcium-independent and may therefore explain
why 2-ciglitazone, which does not potently activate p38, in-
duces EGFR and Erk phosphorylation to the same extent as
ciglitazone. We therefore hypothesize that the failure of the
2-derivatives to potently induce phosphorylation of certain
kinases in GN4 cells is related to their inability to promote ER
calcium release. Consistent with this hypothesis, 2-ciglita-
zone and 2-troglitazone were unable to induce eIF2 phos-
phorylation to the same extent as the parent compounds.
In summary, we provide evidence that the PPAR ligands
ciglitazone and troglitazone activate CaMKII and that this
calcium-activated kinase, as opposed to Pyk2, is essential for
downstream MKK3/6 and p38 phosphorylation. Activation of
MAPKs is correlated with phosphorylation of the ER stress-
sensitive kinase PERK and subsequent eIF2 phosphorylation.
We identify CaMKII as a potential novel regulator of PKR in
response to ER stress and demonstrate that PKR plays a nec-
essary role in activation of the p38 pathway in response to ER
calcium depletion. The ability of ciglitazone and troglitazone to
induce ER stress as well as activation of MAPKs may play an
important role in their effects on cell growth and maturation.
Consistent with earlier studies, we found here that both cigli-
tazone and troglitazone significantly reduced GN4 cell viability
(data not shown). In contrast, rosiglitazone and pioglitazone
not only failed to induce MAPKs and eIF2 phosphorylation in
this cell model, but also were unable to significantly affect GN4
cell viability suggesting that these kinases play a necessary
role in PPAR ligand-induced cell inhibition. Collectively, these
observations suggest that TZDs induce PPAR-independent
signaling events that have potential relevance to the mecha-
nism responsible for their antitumor activity in a variety
of cancers.
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